Literature DB >> 28748552

Erythropoiesis-stimulating agents in sickle cell anaemia.

Jin Han1,2,3, Jifang Zhou3, Vinod Kondragunta1, Xu Zhang1, Robert E Molokie1, Michel Gowhari1, Johara Hassan1, Shivi Jain1, Gregory S Calip3, Victor R Gordeuk1, Santosh L Saraf1.   

Abstract

Entities:  

Keywords:  darbepoetin; erythropoiesis-stimulating agents; erythropoietin; sickle cell anaemia

Mesh：

Substances：

Year:  2017        PMID： 28748552      PMCID： PMC5787037          DOI： 10.1111/bjh.14846

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Erythropoietin for anemia of renal failure in sickle cell disease.

Authors:  M H Steinberg
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

2.  Erythropoietin in anemia of renal failure in sickle cell disease.

Authors:  S D Roger; I C Macdougall; R C Thuraisingham; A E Raine
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

3.  Identification and Validation of a Sickle Cell Disease Cohort Within Electronic Health Records.

Authors:  Daniel E Michalik; Bradley W Taylor; Julie A Panepinto
Journal:  Acad Pediatr       Date:  2016-12-13       Impact factor: 3.107

4.  Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.

Authors:  Jane A Little; Vicki R McGowan; Gregory J Kato; Kristine S Partovi; Jordan J Feld; Irina Maric; Sabrina Martyr; James G Taylor; Roberto F Machado; Theo Heller; Oswaldo Castro; Mark T Gladwin
Journal:  Haematologica       Date:  2006-08       Impact factor: 9.941

5.  Treatment of sickle cell anemia with hydroxyurea and erythropoietin.

Authors:  M A Goldberg; C Brugnara; G J Dover; L Schapira; S Charache; H F Bunn
Journal:  N Engl J Med       Date:  1990-08-09       Impact factor: 91.245

6.  On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.

Authors:  M A el-Hazmi; A al-Momen; S Kandaswamy; S Huraib; M Harakati; F al-Mohareb; A S Warsy
Journal:  Acta Haematol       Date:  1995       Impact factor: 2.195

7.  Sickle cell anemia patients have low erythropoietin levels for their degree of anemia.

Authors:  J B Sherwood; E Goldwasser; R Chilcote; L D Carmichael; R L Nagel
Journal:  Blood       Date:  1986-01       Impact factor: 22.113

8.  Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure.

Authors:  C R Tomson; M E Edmunds; K Chambers; S Bricknell; J Feehally; J Walls
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

9.  Erythropoietin and renal function in sickle-cell disease.

Authors:  A G Morgan; C A Gruber; G R Serjeant
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-11

10.  F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study.

Authors:  R L Nagel; E Vichinsky; M Shah; R Johnson; E Spadacino; M E Fabry; L Mangahas; R Abel; G Stamatoyannopoulos
Journal:  Blood       Date:  1993-01-01       Impact factor: 22.113
  10 in total
  3 in total

1.  Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.

Authors:  Julia Zhe Xu; Swee Lay Thein
Journal:  Blood       Date:  2022-05-19       Impact factor: 25.476

Review 2.  The nephropathy of sickle cell trait and sickle cell disease.

Authors:  Kenneth I Ataga; Santosh L Saraf; Vimal K Derebail
Journal:  Nat Rev Nephrol       Date:  2022-02-21       Impact factor: 42.439

Review 3.  Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research.

Authors:  Scott D Grosse; Nancy S Green; Sarah L Reeves
Journal:  Pediatr Blood Cancer       Date:  2020-09-17       Impact factor: 3.838
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.